Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Carboplatin’s future in breast cancer treatment

The addition of carboplatin to chemotherapy has shown promise in the treatment of triple-negative breast cancer. Sibylle Loibl, MD, PhD, from the University of Frankfurt, Frankfurt, Germany talks to us about her hopes for this agent, discussing a previous study, the Brightness trial (NCT02032277), which demonstrated the efficacy of carboplatin. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.